罗欣药业(002793) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥688,728,623.11, representing a 3.97% increase compared to ¥662,426,362.85 in the same period last year[4]. - The net loss attributable to shareholders decreased to ¥36,661,627.21, a 59.37% improvement from a loss of ¥90,235,051.14 in Q1 2023[4]. - The net profit for the first quarter of 2024 was -49,632,892.41 CNY, compared to -103,502,385.34 CNY in the same period last year, showing an improvement of approximately 52%[20]. - The company reported a total comprehensive income of -48,314,377.49 CNY for the first quarter, compared to -106,871,684.61 CNY in the same quarter last year, indicating a 55% improvement[20]. - Basic and diluted earnings per share were both -0.03 CNY, compared to -0.08 CNY in the previous year[20]. Cash Flow - The net cash flow from operating activities was negative at ¥96,079,755.91, a significant decline of 457.83% compared to a positive cash flow of ¥26,850,638.73 in the previous year[4]. - The company reported a significant decrease in cash received from operating activities, down 71.90% to ¥18,325,259.55 from ¥65,209,714.51 in Q1 2023[9]. - The net cash flow from investing activities was 9,197,783.26 CNY, a decrease from 584,960,373.21 CNY in the previous year[21]. - The net cash flow from financing activities was 84,032,259.64 CNY, compared to -797,934,844.53 CNY in the same period last year, indicating a significant turnaround[22]. Assets and Liabilities - The total assets at the end of Q1 2024 were ¥5,117,183,197.47, showing no significant change from ¥5,117,407,332.82 at the end of the previous year[4]. - Total current assets rose to ¥2,111,895,131.73, up from ¥2,067,511,343.63, marking an increase of 2.1%[16]. - Total liabilities increased to ¥2,693,086,853.36 from ¥2,544,998,012.34, representing a growth of 5.8%[18]. - The company’s total equity attributable to shareholders decreased by 5.48% to ¥2,334,555,189.88 from ¥2,469,901,453.15 at the end of the previous year[4]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,083[11]. - The largest shareholder, Shandong Luoxin Holdings, holds 21.79% of shares, totaling 209,829,196 shares[11]. - The company has repurchased a total of 26,027,861 shares, representing 2.39% of the total share capital[14]. - The repurchase was conducted at a total cost of approximately RMB 99.99 million, with a maximum price of RMB 4.21 per share[14]. - The company plans to use the repurchased shares for employee stock ownership plans or equity incentives[14]. - The top ten shareholders include both domestic and foreign entities, with significant stakes held by natural persons[11]. - The total number of shares held by the top ten unrestricted shareholders is 236,955,520 shares[11]. - The company has set a repurchase fund amounting to no less than RMB 50 million and no more than RMB 100 million[13]. - The repurchase plan is valid for 12 months from the board's approval date[13]. Research and Development - Research and development expenses decreased by 60.53% to ¥15,349,082.71 from ¥38,888,009.55 in Q1 2023, indicating reduced investment in R&D[9]. - Research and development expenses were ¥15,349,082.71, down 60.5% from ¥38,888,009.55 in the previous period[19]. Inventory and Other Assets - Inventory decreased to ¥419,729,072.59 from ¥455,611,306.50, a reduction of 7.9%[16]. - Non-current assets totaled ¥3,005,288,065.74, down from ¥3,049,895,989.19, a decrease of 1.5%[17]. - Cash and cash equivalents increased to ¥723,870,325.69 from ¥692,899,478.54, a rise of 4.5%[16]. - Cash and cash equivalents at the end of the period were 578,525,332.22 CNY, down from 642,998,306.21 CNY at the end of the previous year[22]. Operating Costs - Total operating costs decreased to ¥737,869,165.84 from ¥752,691,953.36, reflecting a reduction of 2.0%[19]. - The company generated 656,674,687.35 CNY from sales of goods and services, a slight decrease from 666,158,367.11 CNY year-over-year[21].